Gastrointestinal agents that stimulate the flow of bile into the duodenum (cholagogues) or stimulate the production of bile by the liver (choleretic).

Primary biliary cirrhosis associated with membranous glomerulonephritis. (1/278)

A 33-year-old woman was admitted to our department for evaluation of liver dysfunction and proteinuria. A liver biopsy specimen showed ductular proliferation and moderate portal fibrosis indicating stage II primary biliary cirrhosis. A renal biopsy specimen showed mild to moderate mesangial cell proliferation without crescent formation or interstitial nephritis. Immunofluorescent staining revealed deposition of immunoglobulin G (IgG), third component of complement (C3), and Clq on glomerular basement membranes. The findings indicated stage I membranous glomerulonephritis. Administration of ursodesoxycholic acid together with prednisolone, azathioprine, and dipyridamole decreased proteinuria and improved cholestatic liver dysfunction.  (+info)

Administration of an unconjugated bile acid increases duodenal tumors in a murine model of familial adenomatous polyposis. (2/278)

Intestinal carcinogenesis involves the successive accumulation of multiple genetic defects until cellular transformation to an invasive phenotype occurs. This process is modulated by many epigenetic factors. Unconjugated bile acids are tumor promoters whose presence in intestinal tissues is regulated by dietary factors. We studied the role of the unconjugated bile acid, chenodeoxycholate, in an animal model of familial adenomatous polyposis. Mice susceptible to intestinal tumors as a result of a germline mutation in Apc (Min/+ mice) were given a 10 week dietary treatment with 0.5% chenodeoxycholate. Following this, the mice were examined to determine tumor number, enterocyte proliferation, apoptosis and beta-catenin expression. Intestinal tissue prostaglandin E2 (PGE2) levels were also assessed. Administration of chenodeoxycholate in the diet increased duodenal tumor number in Min/+ mice. Promotion of duodenal tumor formation was accompanied by increased beta-catenin expression in duodenal cells, as well as increased PGE2 in duodenal tissue. These data suggest that unconjugated bile acids contribute to periampullary tumor formation in the setting of an Apc mutation.  (+info)

Effect of long term simvastatin administration as an adjunct to ursodeoxycholic acid: evidence for a synergistic effect on biliary bile acid composition but not on serum lipids in humans. (3/278)

BACKGROUND: Stimulated bile acid synthesis preferentially utilises newly synthesised cholesterol, raising the possibility that combination of simvastatin (an inhibitor of cholesterol synthesis) with ursodeoxycholic acid (UDCA; a stimulator of bile acid synthesis) may result in reduced bile acid synthesis and greater enrichment of the pool with UDCA than that achieved with UDCA treatment alone. AIMS: To investigate the effect of simvastatin and UDCA given alone and in combination on serum and biliary lipid and biliary bile acid composition. METHODS: Eighteen patients with primary non-familial hypercholesterolaemia were studied during treatment with simvastatin 20 mg/day, UDCA 10 mg/kg/day, and a combination of the two drugs. Each regimen was given in random order for three months following a three month lead in period. RESULTS: Simvastatin significantly reduced serum low density lipoprotein (LDL) cholesterol but biliary cholesterol concentration remained unchanged. Combination of the two drugs had no synergistic effect on serum cholesterol concentration, but significantly increased the proportion of UDCA in the bile acid pool from 35% during UDCA to 48% during combination treatment (p<0.04). CONCLUSIONS: Results showed that: (1) simvastatin reduces serum LDL cholesterol but has no effect on biliary cholesterol concentration, supporting the concept that newly synthesised cholesterol is not the preferential source for biliary cholesterol; and (2) combination of simvastatin with UDCA has the predicted effect of enhancing the proportion of UDCA in the pool. This effect may be of benefit in the treatment of cholestatic liver diseases.  (+info)

Taurocholate-induced inhibition of hepatic lysosomal degradation of horseradish peroxidase. (4/278)

Endocytosed proteins in hepatocytes are transported to lysosomes for degradation. Metabolites accumulating in these organelles are released into bile by exocytosis, a process that seems to be regulated by the bile salt taurocholate (TC). In this study we examined if TC is also involved in the control of the lysosomal degradation of endocytosed proteins. We used [(14)C]sucrose-labeled horseradish peroxidase ([(14)C]S-HRP), a probe suitable to evaluate lysosomal proteolysis. TC-infused rats as well as isolated rat hepatocytes exposed to TC showed a significant inhibition in the lysosomal degradation of [(14)C]S-HRP (approximately 30%), with no change in either the uptake or the amount of protein reaching lysosomes. Under these conditions, the in vitro assay of lysosomal cathepsins B, L, H, and D revealed no change in their activities, suggesting that a reversible inhibition (lysosomal alkalinization?) was taking place in hepatocytes. Nevertheless, lysosomal pH measured using fluorescein isothiocyanate-dextran was shown not to be altered by TC. In addition, TC was unable to inhibit proteolysis in [(14)C]S-HRP loaded lysosomes or interfere in cathepsin assays. The results suggest that TC inhibits the lysosomal degradation of endocytosed proteins in hepatocytes and that the mechanism does not involve an effect of the bile salt per se or a rise in lysosomal pH.  (+info)

Bile acid patterns in meconium are influenced by cholestasis of pregnancy and not altered by ursodeoxycholic acid treatment. (5/278)

BACKGROUND: Data on meconium bile acid composition in newborn babies of patients with intrahepatic cholestasis of pregnancy (ICP) are relatively scant, and changes that occur on ursodeoxycholic acid (UDCA) administration have not been evaluated. AIMS: To investigate bile acid profiles in meconium of neonates from untreated and UDCA treated patients with ICP. Maternal serum bile acid composition was also analysed both at diagnosis and delivery to determine whether this influences the concentration and proportion of bile acids in the meconium. PATIENTS/METHODS: The population included eight healthy pregnant women and 16 patients with ICP, nine of which received UDCA (12.5-15.0 mg/kg body weight/day) for 15+/-4 days until parturition. Bile acids were assessed in the meconium by gas chromatography-mass spectrometry and in maternal serum by high performance liquid chromatography. RESULTS: Total bile acid and cholic acid concentrations in the meconium were increased (p<0.01) in newborns from patients with ICP (13.5 (5.1) and 8.4 (4.1) micromol/g respectively; mean (SEM)) as compared with controls (2.0 (0.5) and 0.8 (0.3) micromol/g respectively), reflecting the total bile acid and cholic acid levels in the maternal serum (r = 0.85 and r = 0.84, p<0.01). After UDCA administration, total bile acid concentrations decreased in the mother ( approximately 3-fold, p<0. 05) but not in the meconium. UDCA concentration in the meconium showed only a 2-fold increase after treatment, despite the much greater increase in the maternal serum (p<0.01). Lithocholic acid concentration in the meconium was not increased by UDCA treatment. CONCLUSIONS: UDCA administration does not influence the concentration and proportion of bile acids in the meconium, which in turn are altered by ICP. Moreover, this beneficial treatment for the mother does not increase meconium levels of potentially toxic metabolites of UDCA such as lithocholic acid.  (+info)

Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. (6/278)

Ursodeoxycholic acid (ursodiol) is a non-toxic, hydrophilic bile acid used to treat predominantly cholestatic liver disorders. Better understanding of the cellular and molecular mechanisms of action of ursodeoxycholic acid has helped to elucidate its cytoprotective, anti-apoptotic, immunomodulatory and choleretic effects. Ursodeoxycholic acid prolongs survival in primary biliary cirrhosis and it improves biochemical parameters of cholestasis in various other cholestatic disorders including primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, cystic fibrosis and total parenteral nutrition-induced cholestasis. However, a positive effect on survival remains to be established in these diseases. Ursodeoxycholic acid is of unproven efficacy in non-cholestatic disorders such as acute rejection after liver transplantation, non-alcoholic steatohepatitis, alcoholic liver disease and chronic viral hepatitis. This review outlines the present knowledge of the modes of action of ursodeoxycholic acid, and presents data from clinical trials on its use in chronic liver diseases.  (+info)

Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study. (7/278)

BACKGROUND: Ursodeoxycholic acid (UDCA) is able to improve biochemical markers of cholestasis, with a parallel decrease in transaminases, in various cholestatic liver diseases. AIM: To evaluate the effects of UDCA administration on acute viral hepatitis-related cholestasis and the course of acute viral hepatitis. METHODS: Seventy-nine consecutive patients with acute viral hepatitis (HBV: 43, HCV: 11, HAV: 15, HEV: 3, Non A-E: 7) were randomized to receive either UDCA for 3 weeks or no treatment. Liver biochemistry and serum bile acid determinations were run at weekly intervals. RESULTS: No significant differences were observed in mean percentage decreases in transaminases between treated and untreated patients. By contrast, cholestatic indexes decreased significantly more quickly in patients treated with UDCA than in controls, and this effect was more evident in patients with increasing alanine transaminase levels at admission. After a peak at the end of the first week of therapy, serum levels of conjugated ursodeoxycholic acid (CUDCA) showed a gradual decrease. Conjugated cholic acid (CCA) and chenodeoxycholic acid (CCDCA) showed a progressive decrease with the resolution of viral hepatitis, but no influence of UDCA administration was observed. CONCLUSIONS: Our study demonstrates that UDCA significantly improves cholestatic indices in patients with acute viral hepatitis, but this effect does not seem to affect the course of the illness.  (+info)

Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment. (8/278)

BACKGROUND: In some patients with primary biliary cirrhosis, ursodeoxycholic acid causes full biochemical normalisation of laboratory data; in others, indexes improve but do not become normal. AIMS: To characterise complete and incomplete responders. METHODS: Seventy patients with primary biliary cirrhosis were treated with ursodeoxycholic acid 10-15 mg/kg/day and followed up for 6-13 years. RESULTS: In 23 patients (33%) with mainly stage I or II disease, cholestasis indexes and aminotransferases normalised within 1-5 years, except for antimitochondrial antibodies. Histological findings improved. Indexes were not normalised in 47 patients (67%) although the improvement of their biochemical functions parallelled the trend in the first group. In these incomplete responders histological findings improved to a lesser extent. The only difference between the two groups before treatment was higher levels of alkaline phosphatase and gamma glutamyl transpeptidase in the incomplete responders. At onset of treatment the discriminant value separating responders from incomplete responders was 660 U/l for alkaline phosphatase and 131 U/l for gamma glutamyl transpeptidase. One year later it was 239 and 27 U/l (overall predictive value for responders 92%, for incomplete responders 81%). There were no differences between the two groups concerning immune status, antimitochondrial antibody subtypes, liver histology, or any other data. HLA-B39, DRB1*08, DQB1*04 dominated in both groups. CONCLUSIONS: In patients with mainly early stages of primary biliary cirrhosis, higher values of alkaline phosphatase and gamma glutamyl transpeptidase are the only biochemical indexes which allow discrimination between patients who will completely or incompletely respond to ursodeoxycholic acid treatment.  (+info)

Cholagogues and choleretics are substances that stimulate the production and flow of bile in the liver and gallbladder. Bile is a greenish-yellow fluid that helps to digest fats and fat-soluble vitamins in the small intestine. Cholagogues and choleretics are often used to treat digestive disorders such as gallstones, jaundice, and fatty liver disease. They can also be used to increase bile flow in people who are taking certain medications that can reduce bile production. Some examples of cholagogues and choleretics include milk thistle, dandelion root, and artichoke leaf extract.

Cholagogues and Choleretics / therapeutic use * Cholangiocarcinoma / etiology * Cholangitis / etiology * Cholangitis, ...
It is used as a cholagogue and choleretic.. Terms. Ursodeoxycholic Acid Preferred Term Term UI T042654. Date01/01/1999. ... It is used as a cholagogue and choleretic.. Entry Term(s). 3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-oic Acid Cholit-Ursan ... Cholagogues and Choleretics. Registry Number. 724L30Y2QR. Related Numbers. 128-13-2. CAS Type 1 Name. Cholan-24-oic acid, 3,7- ...
reduces bloating, aerophagia and flatulences , digestive tonic with light laxative effects , choleretic and cholagogue ... antispasmodic effects , reduces bloating, aerophagia and flatulences , digestive tonic with light laxative effects , choleretic ...
stasis = CHOLESTASIS; drugs stimulating or increasing flow of bile = CHOLAGOGUES AND CHOLERETICS. ...
keywords = "Autoimmune Diseases, Cholagogues and Choleretics, Family Practice, Humans, Liver Diseases, Nurse Clinicians, ...
CHOLAGOGUES AND CHOLERETICS FOR THE TREATMENT OF ALL DISEASES OF THE LIVER AND BILE DUCTS SUCH AS CHOLANGITIS (JAUNDICE…. Owned ...
It is used as a cholagogue and choleretic. AN = /biosyn /defic /physiol permitted; urso- refers to its first isol from bears ( ...
It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.. ...
Cholagogues and Choleretics, Cholangitis, Sclerosing, Humans, Randomized Controlled Trials as Topic, Ursodeoxycholic Acid ...
25 Tea bags , NPN 80001127 ,Traditionally used in Herbal Medicine to help increase bile flow (cholagogue and choleretic); as a ... 50 Grams , NPN 80001187 , Traditionally used in Herbal Medicine as a diuretic to help increase bile flow (choleretic) ; to help ... 75 Grams , NPN 80001141 , Used in Herbal Medicine to help increase bile flow (choleretic) and to help relieve digestive ...
Cholagogue: Stimulating the secretion of bile into the duodenum. *Choleretic: Helps the liver to excrete bile, leading to ...
Plant known for its detoxifying properties and for its cholagogue and choleretic effectiveness. BOLDO. It possesses choleretic ... Plant known for choleretic action, promotes liver function. TURMERIC. The turmeric extract has digestive properties and it can ... Its root is rich in minerals, such as iron, potassium and fiber, its well known for its choleretic action. MILK THISTLE. It ... Plant with diuretic properties, depurative and choleretic able to promote bile secretion. CRISANTELLO. Exerts hepatoprotective ...
CHARACTERIZATION OF THE TECHNOLOGY: A natural biliary acid with cholagogue and choleretic effects. QUESTION: Is ursodeoxycholic ...
Use: (a) Diuretic, whole plant, especially the leaf, (b) Stomachic, (c) Mild laxative, (d) Cholagogue, (e) Choleretic, (f) Anti ...
Charcoal, Cholagogues and Choleretics, Cholestasis, Cholestyramine Resin, Drugs, Chinese Herbal, Galactans, Mannans, Plant Gums ...
... cholagogue and choleretic). Dandelion... ...
Cholagogic: Same as Cholagogue. Cholagogue: An herb or substance that stimulates and in- creases the flow of bile into the ... Choleretic: An herb or substance that prevents or decreases the flow of bile into the intestines.. Cholinergic: An herb or ... Ant: Cholagogue). Anti-biotic: An herb or substance that destroys or arrests the growth of micro-organisms. (Syn: Antiseptic, ...
Igusol Advance SA has developed IGUSAFE WS, soluble powder of plant extracts with choleretic, cholagogue and antioxidant ...
It also has choleretic and cholagogue activity, that is, it promotes the production of bile by the liver and its release in the ...
Cholagogues and choleretics. Demulcents. Depurative. Diaphoretics. Diuretics. Emmenagogues. Expectorants. Febrifuge. ...
Cholagogue essential oils * Choleretic essential oils * Anti-viral essential oils * Anti-spasmotic essential oils ...
Helichrysum Species as Choleretic and Cholagogue Crude Drugs #Bay han Çubukcu Turkish Abstract Abstract Full Text PDF Similar ...
Choleretic, cholagogue, diuretic, tonic, antirheumatic, bitter, alterative, inflammation modulator.. Dandelion purifies the ...
MeSH Terms: Acetophenones/metabolism; Acetophenones/pharmacology*; Animals; Bile/secretion*; Cholagogues and Choleretics/ ... whereas it failed to exert a choleretic effect in TR(-) rats. This choleresis was not explained by increased biliary output of ... and may thus account in large part for the choleretic effects of 4-HA. Transport of this metabolite across the canalicular ...
Cholagogues and Choleretics / adverse effects Actions. * Search in PubMed * Search in MeSH ...
Cholagogues and Choleretics / adverse effects Actions. * Search in PubMed * Search in MeSH ...
This preparation acts as a cholagogue and choleretic and is used in detoxification of the liver. ... These include vasodilators, vitamins and minerals, choleretics and cholagogues, diuretics, and smooth muscle stimulants. ...
Cholagogue Activity,N0000008356, Choleretic Activity,N0000008357, Cholesterol Absorption Alteration,N0000008358, Cholesterol ...
Cholagogues et cholérétiques Entry term(s):. Cholagogues. Cholagogues, Choleretics. Choleretics. Choleretics and Cholagogues. ... Cholagogues and Choleretics - Preferred Concept UI. M0004221. Scope note. Gastrointestinal agents that stimulate the flow of ... Cholagogues and Choleretics Entry term(s). Cholagogues, Choleretics Choleretics and Cholagogues Choleretics - Narrower Concept ... Gastrointestinal agents that stimulate the flow of bile into the duodenum (cholagogues) or stimulate the production of bile by ...
CHOLAGOGUES CHOLERETICS. Entry Term(s). Cholagogues Cholagogues, Choleretics Choleretics Choleretics and Cholagogues ... choleretic).. Terms. Cholagogues and Choleretics Preferred Term Term UI T008008. Date01/01/1999. LexicalTag NON. ThesaurusID ... Choleretics Narrower Concept UI. M0004222. Registry Number. 0. Terms. Choleretics Preferred Term Term UI T008009. Date03/29/ ... Cholagogues Narrower Concept UI. M0004220. Registry Number. 0. Terms. Cholagogues Preferred Term Term UI T008005. Date03/29/ ...
CHOLAGOGUES CHOLERETICS. Entry Term(s). Cholagogues Cholagogues, Choleretics Choleretics Choleretics and Cholagogues ... choleretic).. Terms. Cholagogues and Choleretics Preferred Term Term UI T008008. Date01/01/1999. LexicalTag NON. ThesaurusID ... Choleretics Narrower Concept UI. M0004222. Registry Number. 0. Terms. Choleretics Preferred Term Term UI T008009. Date03/29/ ... Cholagogues Narrower Concept UI. M0004220. Registry Number. 0. Terms. Cholagogues Preferred Term Term UI T008005. Date03/29/ ...
Dandelion is both choleretic, increasing bile production in the liver, and cholagogue, causing the gallbladder to release bile ... "as a hepatic and cholagogue, dandelion has an affinity for the liver, stimulates the gallbladder, and is helpful for relieving ...
Cholagogue (promotes the discharge of bile from the system, purging it downward) ... Choleretic (increases bile flow). Circulatory (supports blood circulation). Cicatrisant (wound healing / formation of a ...
Hypericum perforatum L. and the Underlying Molecular Mechanisms for Its Choleretic, Cholagogue, and Regenerative Properties by ... However, according to traditional Persian medicine, it helps with jaundice and acts as a choleretic medication. Here, we will ...
Cholagogues and Choleretics. *Demulcents. *Emetics. *Guanylyl Cyclase C Agonists. *Laxatives. *Lipotropic Agents ...
... cholagogue and choleretic, cicatrisant, depurative, digestive, disinfectant, emenagogue, expectorant, febrifuge, laxative and ... cholagogue, emenagogue, febrifuge, insecticide, sedative, stomachic, sudorific, and tonic substance. ...
Cholagogue, Choleretic, Deodorant, Diuretic, Expectorant, Hypertensive, Insecticidal, Restorative, Rubefacient, Stimulant ( ... Analgesic, Anesthetic, Antibacterial, Antiseptic, Antiphlogistic, Antispasmodic, Astringent, Carminative, Cephalic, Cholagogue ...
CHOLAGOGUES AND CHOLERETICS TAUROCHOLIC ACID CHOLAGOGUES AND CHOLERETICS TAURODEOXYCHOLIC ACID CHOLAGOGUES AND CHOLERETICS ... CHOLAGOGUES AND CHOLERETICS URSODEOXYCHOLIC ACID CHOLAGOGUES AND CHOLERETICS ALCURONIUM CHOLINERGIC AGENTS AMBENONIUM CHLORIDE ... CHEMOSTERILANTS CHOLAGOGUES AND CHOLERETICS CHOLAGOGUES AND CHOLERETICS TAUROCHENODEOXYCHOLIC ACID ... AND RENA CHOLAGOGUES AND CHOLERETICS HEMATOLOGIC, GASTROINTESTINAL, AND RENA CHOLIC ACIDS HEMATOLOGIC, GASTROINTESTINAL, AND ...
... cholagogue, choleretic, cicatrizing, cordial, cytophylactic, diuretic, emmenagogue, deodorant, hypotensive, insecticide, ... cholagogue, diuretic, expectorant, and antiepileptic effects. It is generally used to manage mental fatigue, circulation- ...
Cholagogue function of bile secretion Current Synonym true false 148125012 Choleretic function of bile secretion Current ...
Helichrysum Species as Choleretic and Cholagogue Crude Drugs #Bay han Çubukcu Turkish Abstract Abstract Full Text PDF Similar ...
  • The effects of 4-HA were also examined in animals treated with buthionine sulfoximine to decrease hepatic glutathione (GSH) levels.In normal rats, 4-HA dramatically increased bile flow rate, whereas it failed to exert a choleretic effect in TR(-) rats. (nih.gov)
  • In contrast to normal rats, this 4-HA metabolite was not present in bile of TR(-) rats.These results demonstrate that the major biliary metabolite of 4-HA in rats is the 4-O-beta-glucuronide, a compound that is secreted into bile at high concentrations, and may thus account in large part for the choleretic effects of 4-HA. (nih.gov)
  • Gastrointestinal agents that stimulate the flow of bile into the duodenum (cholagogues) or stimulate the production of bile by the liver (choleretic). (bvsalud.org)

No images available that match "cholagogues and choleretics"